PMID- 30191652
OWN - NLM
STAT- MEDLINE
DCOM- 20190314
LR  - 20190314
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 36
IP  - 6
DP  - 2018 Dec
TI  - Use of acetazolamide in the treatment of patients with refractory congestive 
      heart failure.
PG  - e12465
LID - 10.1111/1755-5922.12465 [doi]
AB  - AIMS: Optimal diuretic treatment of patients with refractory congestive heart 
      failure (CHF) remains to be elucidated. In this work, we aimed to evaluate the 
      serial changes of functional class and surrogates of fluid overload (weight and 
      antigen carbohydrate 125) after addition of oral acetazolamide in patients with 
      refractory CHF. Likewise, serial changes in renal function, serum electrolytes 
      and pH were evaluated. METHOD: This is an observational retrospective study in 
      which 25 ambulatory patients with refractory CHF that received acetazolamide in 
      addition to standard intensive diuretic strategy were evaluated. Longitudinal 
      assessment of New York Heart Association (NYHA) functional class and biomarkers 
      was analyzed using joint modelling of longitudinal and survival data. RESULTS: 
      All patients showed NYHA class III/IV at baseline. After prescription of 
      acetazolamide, a total of 125 outpatient visits were recorded [median visits per 
      patient: 6 (IQR = 3-7)] during a median follow-up of 152 days (IQR = 80-353). A 
      significant decrease in NYHA class, weight, and antigen carbohydrate 125 was 
      observed. On the other hand, estimated glomerular filtration rate increased over 
      time. No significant changes in systolic blood pressure, serum sodium, potassium, 
      amino-terminal pro-brain natriuretic peptide, and pH occurred. CONCLUSION: In a 
      cohort of patients with refractory CHF treated with an intensive diuretic 
      treatment, the addition of acetazolamide was associated with improvement in 
      functional class and surrogates of fluid overload.
CI  - (c) 2018 John Wiley & Sons Ltd.
FAU - Nunez, Julio
AU  - Nunez J
AUID- ORCID: 0000-0003-1672-7119
AD  - Cardiology Department, Hospital Clinico Universitario de Valencia, INCLIVA, 
      Departamento de Medicina, Universitat de Valencia, Valencia, Spain.
AD  - CIBER in Cardiovascular Diseases (CIBERCV), Madrid, Spain.
FAU - Heredia, Raquel
AU  - Heredia R
AD  - Cardiology Department, Hospital Clinico Universitario de Valencia, INCLIVA, 
      Departamento de Medicina, Universitat de Valencia, Valencia, Spain.
FAU - Paya, Ana
AU  - Paya A
AD  - Cardiology Department, Hospital Clinico Universitario de Valencia, INCLIVA, 
      Departamento de Medicina, Universitat de Valencia, Valencia, Spain.
FAU - Sanchis, Ignacio
AU  - Sanchis I
AD  - Cardiology Department, Hospital Clinico Universitario de Valencia, INCLIVA, 
      Departamento de Medicina, Universitat de Valencia, Valencia, Spain.
FAU - Del Prado, Susana
AU  - Del Prado S
AD  - Cardiology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.
FAU - Minana, Gema
AU  - Minana G
AD  - Cardiology Department, Hospital Clinico Universitario de Valencia, INCLIVA, 
      Departamento de Medicina, Universitat de Valencia, Valencia, Spain.
FAU - Santas, Enrique
AU  - Santas E
AD  - Cardiology Department, Hospital Clinico Universitario de Valencia, INCLIVA, 
      Departamento de Medicina, Universitat de Valencia, Valencia, Spain.
FAU - de la Espriella, Rafael
AU  - de la Espriella R
AD  - Cardiology Department, Hospital Clinico Universitario de Valencia, INCLIVA, 
      Departamento de Medicina, Universitat de Valencia, Valencia, Spain.
FAU - Nunez, Eduardo
AU  - Nunez E
AD  - Cardiology Department, Hospital Clinico Universitario de Valencia, INCLIVA, 
      Departamento de Medicina, Universitat de Valencia, Valencia, Spain.
FAU - Sanchis, Juan
AU  - Sanchis J
AD  - Cardiology Department, Hospital Clinico Universitario de Valencia, INCLIVA, 
      Departamento de Medicina, Universitat de Valencia, Valencia, Spain.
AD  - CIBER in Cardiovascular Diseases (CIBERCV), Madrid, Spain.
FAU - Bayes-Genis, Antoni
AU  - Bayes-Genis A
AD  - CIBER in Cardiovascular Diseases (CIBERCV), Madrid, Spain.
AD  - Heart Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
AD  - Department of Medicine, Universitat Autonoma de Barcelona, Barcelona, Spain.
LA  - eng
GR  - 16/11/00420/CIBER CV/
GR  - 16/11/00403/CIBER CV/
GR  - FEDER/
GR  - 15/00013/PIE/
PT  - Journal Article
PT  - Observational Study
DEP - 20180929
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Biomarkers)
RN  - 0 (CA-125 Antigen)
RN  - 0 (Diuretics)
RN  - O3FX965V0I (Acetazolamide)
SB  - IM
MH  - Acetazolamide/*administration & dosage/adverse effects
MH  - Administration, Oral
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers/blood
MH  - CA-125 Antigen/blood
MH  - Diuretics/*administration & dosage/adverse effects
MH  - Feasibility Studies
MH  - Female
MH  - Glomerular Filtration Rate/drug effects
MH  - Heart Failure/blood/diagnosis/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Recovery of Function
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Water-Electrolyte Balance/drug effects
MH  - Weight Loss/drug effects
OTO - NOTNLM
OT  - acetazolamide
OT  - congestion
OT  - diuretics
OT  - feasibility
OT  - fluid overload
OT  - refractory congestive heart failure
EDAT- 2018/09/08 06:00
MHDA- 2019/03/15 06:00
CRDT- 2018/09/08 06:00
PHST- 2018/07/27 00:00 [received]
PHST- 2018/08/25 00:00 [revised]
PHST- 2018/09/03 00:00 [accepted]
PHST- 2018/09/08 06:00 [pubmed]
PHST- 2019/03/15 06:00 [medline]
PHST- 2018/09/08 06:00 [entrez]
AID - 10.1111/1755-5922.12465 [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2018 Dec;36(6):e12465. doi: 10.1111/1755-5922.12465. Epub 2018 
      Sep 29.